Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for choroidal neovascularization due to pseudoxanthoma elasticum
2006-006231-49Phase 2Completed
- Sponsor
- University Eye Hospital Bonn
- Start
- Mar 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab in Subretinal neovascularization and pseudoxanthoma elasticum (PXE), sponsored by University Eye Hospital Bonn. Primary endpoint: Visual acuity. Started Mar 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
Subretinal neovascularizationpseudoxanthoma elasticum (PXE)
Beyond the preview
Go deeper on 2006-006231-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006231-49.